AbilityPharma closes a €7 million investment round led by Inveready
Bio-pharmaceutical company AbilityPharma announces a €7 million investment from a European Canadian syndicate of life sciences investors
Barcelona, March 11, 2024
Bio-pharmaceutical company AbilityPharma, which develops innovative oral drugs for cancer treatment focusing on autophagy as a new therapeutic strategy to induce selective death of cancer cells, announces a €7 million investment from a European Canadian syndicate of life sciences investors led by CTI Life Sciences Fund, Inveready, and EIC Fund, with participation from CDTI Innvierte and FiTalent.
13/03/2023
AbilityPharma closes a €7 million investment round led by Inveready
Bio-pharmaceutical company AbilityPharma announces a €7 million investment from a European Canadian syndicate of life sciences investors